Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI).
- Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI).
- The current standard of care for advanced DR includes intravitreal anti-VEGF treatment or invasive laser treatment.
- “Retinal non-perfusion is a key driver of vision loss in people living with diabetic retinopathy.
- However, until the HORNBILL study, retinal non-perfusion has not been explored as a potential treatment target.”
“Vision loss associated with retinal conditions such as diabetic retinopathy and DMI has a devastating impact on quality of life.